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Introduction/overview
Subcutaneous human adipose tissue is an abundant and 
accessible cell source for applications in tissue engineer-
ing and regenerative medicine. Investigators have 
explored methods to extract stromal/stem cells from the 
waste products of abdominoplasty, cosmetic surgery, and 
tumescent liposuction procedures. Routinely, the adipose 
tissue is digested with collagenase or related lytic 
enzymes to release a heterogeneous population of 
stromal vascular fraction (SVF) cells. Th  e SVF cells can 
be used directly or can be cultured in plastic ware to 
select and expand an adherent population known as 
adipose-derived stromal/stem cells (ASCs).
During the past decade, the body of literature relating 
to the isolation, characterization, diﬀ  erentiation, expan-
sion, immunophenotype, immunomodulatory properties, 
and preclinical use of SVF cells and ASCs has increased 
dramatically (reviewed in [1-4]). Th  ese studies, con-
ducted throughout the globe, have provided evidence on 
the safety and eﬃ   cacy of SVF cells and ASCs in vivo using 
animal models. With these reproducible and indepen-
dently generated data, regulatory authorities in multiple 
countries have permitted a limited number of clinical 
trials involving SVF cells and ASCs to move forward. Th  e 
present concise review will focus on publications relating 
to these ongoing clinical trials, their outcomes, and the 
future clinical translation of adipose-derived, cell-based 
tissue engineering.
Background
Both ASCs and SVF cells have been used in preclinical 
models to treat acute and chronic diseases aﬄ   icting a 
range of tissues and organs as summarized in Table 1; 
this summary is by no means a complete survey of this 
extensive and emerging body of literature. Th  e  majority 
of preclinical studies using ASCs and SVF cells have been 
conducted in rodent models due to their size, cost, 
availability of antibody probes, and access to inbred, 
genetically modiﬁ  ed, and transgenic strains. A small, but 
growing, number of experiments have sought to evaluate 
the impact of adipose-derived cells in large animal 
disease models; however, these studies in the dog, goat, 
horse, pig, rabbit, or sheep have been hampered by the 
lack of appropriate monoclonal antibody reagents for cell 
tracking and immunophenotypic characterization. Never-
theless, the data accumulated have been suﬃ   cient  to 
allow clinical investigators to apply for regulatory approval 
of clinical trials in many countries around the world.
Before beginning clinical trials, it has been necessary to 
develop current good manufacturing practices for the 
production of clinical-grade human SVF cells and ASCs. 
Th  e Food and Drug Administration [5], the European 
Medicines Agency [6], and other national regulatory 
authorities have developed guidelines for industry 
speciﬁ  cally for adult cell production that are generally 
considered biological products as opposed to devices or 
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In general, cell products are divided into those that are 
minimally manipulated (such as autologous unfraction-
ated circulating blood cells) or those that more than 
minimally manipulated (culture-expanded allogeneic 
bone marrow mesenchymal stem cells). Th  erapies  involv-
ing minimally manipulated cells can advance more 
rapidly to the clinic. Nevertheless, both products face 
similar oversight requirements with respect to testing for 
contaminants.
All products must be evaluated for aerobic and 
anaerobic bacteria, endotoxin, and mycoplasma. If the 
cells are used for allogeneic purposes, either tissue 
donors or the cells themselves must be screened for a 
panel of viral agents, including cytomegalovirus, Epstein–
Barr virus, hepatitis A and C, and HIV. Th  e manu-
facturing process must deﬁ   ne the distinct biological 
characteristics of the cells, and their stability throughout 
the isolation, storage, and shipping process, and must 
provide quality assurance/control of the various compo-
nents used. Th   e manufacturing facility must meet 
rigorous standards with respect to its construction. Th  e 
facility must monitor air handling, ambient temperature, 
humidity, water source and quality. Th  e operating site 
itself must meet construction standards concerning 
ﬂ   oor  ing and wall materials, sealing between surfaces, 
traﬃ   c ﬂ  ow between designated clean and dirty rooms, 
and maintenance of positive air pressure gradients 
between such spaces. To insure that the facility meets 
these standards, the operators are required to monitor 
particle counts per cubic meter of air on a routine basis 
and to maintain records certifying the continuous opera-
tion of the equipment within designated environmental 
parameters. Likewise, the scientiﬁ  c equipment, instru-
ments, and materials need to meet similar standards. Th  e 
operation of all biological safety cabinets, incubators, 
water baths, and related equipment must be certiﬁ  ed at 
least annually. All standard operating procedures must 
be documented. Th  ese documents must provide a 
detailed description of all routine laboratory methods 
as well as those activities required to support the 
manufacturing space, such as cleaning of biological 
safety cabinets and incubators, mopping of ﬂ  oors, walls 
and ceilings, and receipt and storage of perishable and 
nonperishable materials. By design, standard operating 
procedures should be written in a format that allows 
anyone knowledgeable in the ﬁ   eld to conduct the 
procedures independently, with minimal oversight. 
Needless to say, the costs to meet the requirements for 
current good manufacturing practice certiﬁ  cation are 
substantial.
Table 1. Representative preclinical animal studies using adipose-derived stromal/stem cells and stromal vascular fraction cells
Tissue type  Defect  Species  References
Adipose/soft tissue  Fat pad generation  Murine, rat, ovine  [51-60]
 Lipodystrophy  Murine  [48,61]
 Burn/radiation  trauma  Murine  [62-64]
Bone  Critical sized defect   
   Craniofacial  Murine,  rat  [65,66]
   Long  bone  Murine  [67]
 Spinal  fusion  Rat  [68,69]
Cardiac  Myocardial infarction  Murine, rat  [42,43,70,71]
Central nervous system  Vascular injury/stroke  Murine, rat  [44,46,72]
  Spinal cord trauma  Rat  [47]
 Multiple  sclerosis  Murine  [33]
Gastrointestinal tract  Crohn’s disease/infl  ammatory bowel syndrome  Murine  [73]
Hematopoiesis  Bone marrow transplantation  Murine  [74,75]
Joint  Osteoarthritis  Canine, caprine, equine  [76-79]
Liver Acute  toxicity/regeneration  Murine  [80-88]
Pancreas  Type 1 diabetes mellitus  Murine, rat  [48,89,90]
Renal  Acute ischemia  Rat  (JMG, unpublished)
Skin  Wounds, burns  Murine, porcine  [62,64,91]
Tendon Tendonitis  Equine [92]
Urinary bladder  Incontinence  Rat  [93]
Vascular  Hind limb ischemia  Murine, rat  [36,41,45]
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adipose-derived cell products directly available to the 
surgeon in the operating room. To meet this need, Cytori 
Th   erapeutics (San Diego, CA, USA) and Tissue Genesis 
(Honolulu, HI, USA) have designed and manufactured 
devices with a single, closed, disposable container that is 
used to harvest, to collagenase digest, to centrifuge, and 
to separate the lipoaspirate into mature adipocytes and 
SVF cells within a short time frame (1 hour or less) [7,8]. 
Th   ese SVF cells, which fulﬁ  ll many if not all criteria for a 
minimally manipulated product, can then be reintro-
duced into the donor for cosmetic, reconstructive, or 
other purposes by the surgeon. Tissue-processing devices 
are now marketed in Europe and Asia, and are under 
regulatory review for distribution in the US. It will be 
important to monitor outcomes from procedures em-
ploy  ing these devices in the next decade. Although these 
devices are designed to guarantee consistent and 
reproducible results, it remains to be determined 
whether the operator technique introduces any variability 
with respect to surgical procedures using SVF cells.
Published clinical study reports
Soft tissue cosmetic and reconstructive surgery
Soft tissue repair is a logical application – and, theoreti-
cally, the simplest application – for adipose-derived cell 
therapies since the isolated cells presumably do not need 
to display any transdiﬀ  erentiation potential. Both ASCs 
and SVF cells have been approved and employed in 
clinical trials involving soft tissue defects (summarized 
along with other published clinical studies in Table 2). 
Breast reconstruc  tion or augmentation trials have 
enrolled the greatest number of patients. Plastic surgeons 
at the University of Tokyo have reported pioneering 
results using SVF cells in combination with intact 
lipoaspirate tissues. Yoshimura and colleagues have 
combined SVF cells with lipo  aspi  rates from equal 
volumes of tissue to augment breast volume [9-11]. In 
their clinical population of >70 subjects, these authors 
note improved fat grafting in the presence of the SVF 
cells with retention of volume for >1 year without 
evidence of ﬁ  brosis or adhesions. Complica  tions such as 
cyst formation or microcalciﬁ  cations occur in less than 2 
to 3% of patients. Clinical trial reports in abstract form 
conducted by surgeons in Spain, South Korea, and 
elsewhere suggest similar outcomes [12].
It will be necessary to monitor patients for an extended 
period postoperatively. Some clinicians have raised con-
cerns that morphological changes resulting from SVF 
cell/fat graft implants will complicate mammographic 
surveillance for breast cancer in recipients [13]. In 
addition, multiple studies have demonstrated that ASCs 
release growth factors/cytokines that attenuate the innate 
immune response [14-16]. Because of this immuno-
suppressive function, it is possible that the introduction 
of ASCs into breast tissue will create a microenvironment 
that favors or promotes the growth of rare tumor cells 
[17]. Long-term studies will therefore be required to 
compare the incidence of breast cancer in SVF cell-
implanted and ASC-implanted patients with the inci-
dence in untreated controls.
Breast cancer patients often undergo radiation treat-
ment to the axilla post mastectomy, and this can be 
complicated by progressive ﬁ  brotic lesions of the exposed 
skin and dermis, resulting in an impaired range of motion 
in the upper extremity. In pilot clinical studies, surgeons 
have noted signiﬁ   cant improvements following subcu-
taneous autolo  gous fat transplants [18]. Recipients with 
chronic open lesions of the skin prior to treatment healed 
over time, characterized by enhanced microcapillary 
growth at the histological level. Th   e irradiated skin at the 
transplan  tation sites became more supple, allowing the 
patients to recover an increased range of motion in their 
arm. Th   ese changes have been attributed to the presence 
of SVF cells and ASCs in the fat graft. It is likely that 
similar approaches may beneﬁ   t subjects with chronic 
Table 2. Published clinical case reports and clinical trials
Indication  Study type  Number of patients  Follow-up period  References
Soft tissue       
  Breast augmentation  Case reports  403  Up to 6 years  [9-11] (K Yoshimura, personal communication, 
         University  of  Tokyo)
  Craniofacial  Case reports  58  9 to 13 months  [10,21] (K Yoshimura, personal communication, 
         University  of  Tokyo)
  Irradiation fi  brosis  Case reports  20  31 months  [18]
Orthopedic      
  Craniofacial  Case reports  2  >12 months  [25,26]
Immune      
  Crohn’s disease  Phase I  5 to 9  12 to 30 months  [27-31]
  Multiple sclerosis  Case reports  3  7 months  [33]
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bedridden patients and diabetic patients.
While plastic surgeons have used autologous fat grafts 
for over a century, there is substantial variability 
between surgeons with respect to the success of these 
procedures [19,20]. Th  e fat grafts often lose volume, 
undergo ﬁ  brosis, or lead to necrosis. Th   e University of 
Tokyo group used SVF cell/fat graft transplantation to 
treat craniofacial lipodystrophic and cosmetic defects 
with a high degree of success [21]. Th   is suggests that the 
presence of the SVF cells, possibly due to their release 
of cytokines, improves the autologous fat graft viability 
and implantation. Th   is hypothesis may reﬂ  ect the ability 
of the SVF cells/ASCs to improve angiogenesis/
vascularity around the implant, to scavenge reactive 
oxygen species, and/or to enhance adipocyte progenitor 
survival, proliferation, and diﬀ  eren  tiation.
Orthopedics
Th   e use of SVF cells and ASCs for bone repair has been a 
target for many investigators. Th  ere are close develop-
mental links between adipose tissue and bone, and it has 
been postulated that an inverse or reciprocal relationship 
exists between adipogenesis and osteogenesis at the 
cellular level [22-24].
Investigators at the Universities of Tampere and 
Helsinki (Finland) published exciting clinical translational 
outcomes using autologous ASCs to repair a craniofacial 
defect [25]. Th   e patient was a 68-year-old male who had 
lost part of the hard palate of the mouth following 
removal of a cyst. Th  e resulting defect left the subject 
with  out the ability to chew or drink eﬀ  ectively.  To 
address this defect, the surgical team harvested 200 g 
autologous subcutaneous adipose tissue, isolated and 
culture expanded the ASCs in autologous serum, and 
seeded them in the presence of bone morphogenetic 
protein 2 onto a β-tricalcium phosphate scaﬀ  old 
fashioned into the shape of the lesion/defect. Th  e  ASC/
scaﬀ  old construct was implanted into the patient’s rectus 
abdominis muscle and followed for evidence of 
mineralization radiographically over an 8-month period. 
At that time, the construct was resected and transplanted 
to the maxillofacial defect, where its intact epigastric 
artery blood supply was re-anastomosed to the facial 
artery. Subsequently, the ASC/scaﬀ  old implant integrated 
into the bone site with the formation of a normal oral 
epithelium and achieved suﬃ   cient structural stability to 
allow for the implantation of prosthetic teeth. Th  e  patient 
recovered full oral function and remained complication 
free for at least 1 year.
Th  is case represents the ﬁ  rst peer-reviewed report of 
SVF cells or ASCs employed for the complete clinical 
repair of a craniofacial or orthopedic defect [25]. Since 
this case report, the surgical team has conducted similar 
surgeries on >20 subjects with >90% positive outcomes. 
Th   is initial approach has used ASCs for bone repair in a 
nonweight-bearing site. It will be necessary to develop 
techniques that reduce the number of invasive surgeries 
required for each procedure. In this context, a case report 
was published in 2004 describing the repair of a chronic 
calvarial defect in a single operation using autologous 
ASCs in combination with an autologous bone graft and 
ﬁ  brin glue; the reproducibility of this surgical approach 
needs to be validated [26]. Furthermore, it remains to be 
determined whether satisfactory outcomes can be 
achieved using ASCs or SVF cells in the repair of critical-
sized defects in long bones.
Immune disease
Crohn’s disease is an inﬂ   ammatory bowel disorder 
characterized by bloody stools, diarrhea, weight loss, and 
autoimmune-related symptoms. A particularly troubling 
complication for many patients is the development of 
ﬁ  stulas between the bowel and the genitourinary tract. 
Th  e  ﬁ  stulas display a poor rate of healing and often recur. 
Clinicians at the Autonomous University of Madrid have 
explored both autologous SVF cell-based and autologous 
ASC-based therapies for ﬁ   stula repair [27-32]. Th  eir 
approach has been to inject 50% of their recovered cells 
2 mm under the epithelium along the ﬁ  stula track. Th  e 
remaining cells are then combined with ﬁ  brin glue and 
used to ﬁ  ll in the ﬁ  stula directly. In multiple publications 
reporting on phase I trials involving four or ﬁ  ve patients 
each, the Madrid team was able to heal 75% of chronic 
ﬁ  stulas using culture-expanded ASCs. In a single trial of 
four patients, however, they only achieved a 25% repair of 
ﬁ   stulas with nonexpanded SVF cells. Th  ey postulated 
that this might be related to the diﬀ  erence between the 
reported immunogenic properties of ASCs and SVF cells. 
While ASCs display immunosuppressive features and low 
expression of immunoreactive surface antigens in vitro, 
SVF cells lack any immunosuppressive function and 
stimulate T-cell proliferation in parallel assays. In light of 
the autoimmune etiology of Crohn’s disease, these 
immuno  modulatory features could account for the 
relative success or failure of the two adipose-derived cell 
populations.
Multiple sclerosis is a progressive inﬂ  ammatory disease 
aﬀ   ecting the myelinated cells of the central nervous 
system. Over time, this disease leads to degenerative 
changes and loss of cognitive, motor and sensory func-
tion; often, these changes occur in a waxing and waning 
manner. While the etiology of the disease remains in 
question, there is compelling evidence supporting a role 
for an autoimmune component. Th   is has been supported 
by a preclinical model of the disease known as experi-
mental autoimmune encephalitis, whereby a multiple 
sclerosis-like symptomatology is induced by injection of 
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myelin oligodendrocyte glycoprotein [33]. Based on this 
autoimmune association, clinical investigators in Costa 
Rica have begun phase I safety trials treating multiple 
sclerosis patients with intravenous administration of 
autologous SVF cells [34]. In their initial report, the 
investigators provide case reports on three individuals 
who each received two intravenous infusions, each of 25 
to 75 million SVF cells. All patients tolerated the 
treatment without complications, and some experienced 
an improvement in symptoms.
Th   ese preliminary trials need to be followed rigorously 
with appropriate controls to insure both safety and 
eﬃ     cacy. It remains to be determined whether the 
immuno  modulatory functional diﬀ  erences between SVF 
cells and ASCs have relevance. It is possible that ASCs, 
which show evidence of immunosuppressive function, 
may be capable of suppressing the inﬂ  ammatory features 
of multiple sclerosis more eﬀ   ectively than SVF cells. 
Additional preclinical modeling may help to address this 
issue.
Future directions and challenges
Peripheral vascular disease provides a promising target 
for adipose-derived cell therapies. Pioneering preclinical 
studies simultaneously published independently by 
groups in Indianapolis, Toulouse, and Frankfurt – and 
later conﬁ   rmed by others in Japan and Korea – have 
demonstrated the protective eﬀ  ects of both SVF cells and 
ASCs against acute vascular injuries [35-41]. Using 
rodent hind-limb ischemia models, these investigators 
unequivocally demonstrated that intravenous infusion or 
intramuscular injection of adipose-derived cells acceler-
ated recovery of blood supply to the damaged tissues and 
prevented necrosis over a 1-week period. Th  e investi-
gators concluded that production of the angiogenic/
vasculogenic cytokines hepatocyte growth factor and 
vascular endothelial growth factor accounted, in part, for 
the mechanism underlying the ASC and/or SVF cell 
actions [37,40]. Th  ese preclinical studies suggest that 
ASCs and SVF cells could be used to treat claudication 
and chronic vascular insuﬃ   ciency in the lower extremi-
ties, such as that seen in patients with diabetes and 
related small-vessel diseases. Consequently, doctors at 
academic medical centers have begun to submit protocols 
to their national regulatory authorities for translational 
clinical trials; however, to date, no phase I safety or 
eﬃ   cacy results have been published.
Acute diseases
Since the adipose-derived cell secretome contains angio-
genic and vasculogenic cytokines with regenerative and 
neurotrophic properties, there has been considerable 
interest in testing the impact of ASCs and SVF cells on 
acute disorders. Transient ischemic injury underlies the 
pathophysiology of myocardial infarction, stroke, renal 
ischemia, obstruction of the small intestine by intus-
susuception or volvulus, and related conditions asso-
ciated with trauma to the brain, spinal cord, and extremi-
ties. Because these conditions develop rapidly, it follows 
that there is a narrow window of opportunity following 
the ischemic event to attenuate any pathological conse-
quences. Th   eoretically, this window of time may close as 
reactive oxygen species are generated when postischemic 
reperfusion is established. In preclinical animal myo-
cardial infarc  tion models, ASC treatment shortly after 
the event improves ventricular function as compared with 
untreated controls or experimental groups where treat-
ment was delayed [42,43]. In stroke models, ASC infusion 
during the immediate postischemic period accelerated 
recovery of motor function in rats [44-46]. Additional 
studies have explored the regenerative capacity of ASCs 
in models of spinal cord injury [47]. Nevertheless, while 
phase I trials using ASCs or SVF cells have been 
registered for each of these clinical diseases, outcome 
data have been limited to abstract presentations at 
national and international meetings.
Chronic diseases
Th  eoretically, acute diseases present situations where 
rapid intervention can most eﬃ   ciently  prevent  the 
develop  ment of long-term pathologies. In contrast, 
chronic diseases may be less amenable to cell-based 
therapies. Preclinical animal models suggest that adult 
stem cells of bone marrow origin can be used to treat 
type 1 diabetes mellitus, chronic heart failure, and neuro-
degenerative diseases due to inborn errors of metabolism 
(Krabbe’s disease, among others). Since these chronic 
diseases account for the majority of healthcare costs in 
most national economies, there is interest in using ASCs 
and SVF cells for their treatment.
Th  ere is particular interest in the use of ASCs and 
adipose transplantation therapy for lipodystrophy and 
associated metabolic disorders such as diabetes [48]. A 
single group in India has reported improved insulin 
sensitivity in group of ﬁ  ve diabetic patients co-infused 
with ASCs and unfractionated cultured bone marrow 
cells [49]; however, the majority of studies have been 
limited to animal models. For example, our group has 
begun to explore the use of ASC therapy in murine and 
nonhuman primate models of Krabbe’s disease (BA 
Bunnell and JM Gimble, unpublished data). After such 
small and large preclinical animal model data supporting 
the safety and eﬃ   cacy of these approaches are reviewed, 
it will be possible to begin testing adipose-derived cells in 
these important human conditions. A positive outcome 
in a single disease alone could have substantial economic 
and public health beneﬁ  ts.
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Th  e application of ASCs and SVF cells is still in its 
infancy and the ﬁ   eld has made progressive advances 
towards clinical applications. In general, the clinical 
investi  gators who have published their ﬁ  ndings  have 
taken pains to address the important regulatory questions 
before advancing from animal models to patients. Th  ese 
researchers are to be applauded for treating the regula-
tory guidelines not as roadblocks but as oppor  tunities for 
documenting the safety of their cell-based products. Still, 
there have not been many published safety studies 
address  ing the legitimate concerns of regulatory authori-
ties that include the following questions.
Can human ASCs and SVF cell implants cause tumors 
either directly through transformation or indirectly by 
promoting the growth of endogenous tumor cells? At 
least one manuscript has reported that human ASCs 
expanded long term in vitro will cause sarcomas when 
implanted in vivo in an immunodeﬁ  cient mouse [50].
Has a current good manufacturing practice scheme of 
manufacture been developed for the cell products? While 
this information must be available to support existing 
clinical trials, details of standard operating protocols 
have not been made public. International standardization 
of ASCs and SVF cells would signiﬁ  cantly  advance 
clinical translation. Published deﬁ   nition of the cell 
identity with a panel of surface antigens and 
establishment of universally applied quality assurance/
quality control testing criteria would beneﬁ  t the ﬂ  edgling 
adipose stem cell community.
As discussed above, there is no shortage of diseases – 
both acute and chronic – where adipose-derived cell 
therapies could have a potential clinical impact. Th  e  next 
steps will include documenting the reproducibility of the 
current preclinical and clinical ﬁ   ndings, and controlled 
testing of the safety and eﬃ   cacy of ASCs and SVF cells in a 
range of human conditions. In another decade, we postu-
late that the cells will prove beneﬁ  cial to some, but not all, 
of the disease models tested. We expect initial successes to 
come in applications relating to acute disorders; however, 
we are hopeful that chronic diseases amenable to SVF cell 
therapy or ASC therapy will also be identiﬁ  ed.
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